Pyruvate dehydrogenase kinase (PDK) (PDK)

Pyruvate dehydrogenase kinases (PDKs) are essential mitochondrial enzymes that regulate the activity of the pyruvate dehydrogenase complex (PDC), the gatekeeper of aerobic glucose oxidation (UniProt: Q15118, Q15119, Q15120, Q16654). By phosphorylating the E1 subunit of PDC, PDKs inhibit the conversion of pyruvate into acetyl-CoA, effectively shifting cellular metabolism from mitochondrial oxidative phosphorylation to aerobic glycolysis (Jeoung, 2015, Diabetes & Metabolism Journal). This metabolic reprogramming, known as the Warburg effect, is frequently exploited by cancer cells to support rapid proliferation and survival in hypoxic environments (Zhang et al., 2014, Journal of Cancer). In humans, four isoforms (PDK1, PDK2, PDK3, and PDK4) exist with distinct tissue distributions and regulatory roles in metabolic diseases such as type 2 diabetes and heart failure (Stacpoole, 2017, Metabolism). Therapeutic targeting of PDKs with small molecule inhibitors like dichloroacetate aims to reactivate PDC, thereby restoring normal mitochondrial function and promoting apoptosis in malignant cells (Stacpoole, 2017, Metabolism).

Other names

Pyruvate dehydrogenase [lipoamide] kinase[Pyruvate dehydrogenase (acetyl-transferring)] kinaseMitochondrial pyruvate dehydrogenase kinase

Inhibition of PDK prevents the phosphorylation of the E1 subunit of the pyruvate dehydrogenase complex (PDC), thereby maintaining PDC in its active state to promote the conversion of pyruvate to acetyl-CoA for entry into the TCA cycle.